Navigation Links
Maxygen to Host Fourth Quarter and Year End 2007 Financial Results Conference Call on February 12, 2008

REDWOOD CITY, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, will host a conference call to discuss the company's fourth quarter and year end 2007 financial results at 11:30 a.m. ET (8:30 a.m. PT) on Tuesday, February 12, 2008. Russell Howard, Maxygen's chief executive officer, will host the call. A press release announcing Maxygen's fourth quarter and 2007 financial results will be issued that same day at approximately 9:00 a.m. ET.

The call will include discussion of non-GAAP financial measures. Reconciliation of the non-GAAP financial measures to the most directly applicable GAAP measures can be found in the press release announcing Maxygen's fourth quarter and 2007 financial results. This press release will be available February 12, 2008 on Maxygen's website at

Participants in the U.S. can access the call by dialing 866.825.3209 and using the passcode 31366535. International participants can dial 617.213.8061 and use the same passcode. A live webcast of the conference call will be available at

A telephone replay of the conference call will be available until March 12, 2008. To access the replay, please call 888.286.8010 (U.S.) or 617.801.6888 (international) and use the passcode 60709469. An archived version of the webcast will be available until March 12, 2008 at

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Our lead program, MAXY-G34, is designed to be an improved version of G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in our pipeline is a novel Factor VIIa for the treatment of hemophilia. Maxygen's approach to drug discovery and development may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage translates to a greater chance of successfully bringing important new drugs to market.

SOURCE Maxygen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. One-fourth of HIV patients believe their doctors stigmatize them
2. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
3. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
4. Hillenbrand Industries Announces Fourth Quarter 2007 Dividend
5. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
6. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
7. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
8. Health Insurance Premium Growth Slows for Fourth Straight Year
9. Dynatronics Announces Strong Fourth Quarter Profit
10. inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes
11. BD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 ... ... manufacturer, launched offering factory direct sauna parts and accessories. , Sauna accessories ... representative of the bather’s style and personality. From basic styles for the purist ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, ... Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil ... for the opening of the 5th African Network for Drugs and Diagnostics Innovation, ...
(Date:11/25/2015)... Friendswood, TX (PRWEB) , ... November 25, 2015 , ... ... through the companies’ “ Two Organizations, One Beat ” campaign. The partnership between the ... its services to aid in MAP International’s cause. , MAP International was founded in ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology: